{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:28:20Z","timestamp":1772119700347,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Municipal Health Commission of Shanghai Minhang","award":["2020MW16"],"award-info":[{"award-number":["2020MW16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the expression of nuclear receptor subfamily 1 group D member 1 (NR1D1) and nuclear receptor subfamily 2 group E Member 3 (NR2E3) in retinoblastoma (RB) and their correlation with the clinical and pathological features of RB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Immunohistochemical (IHC) assays were performed to detect and evaluate the expression levels of NR1D1 and NR2E3 in paraffin-embedded tissue samples. The relationship between the expression levels and clinicopathological characteristics of RB patients was analyzed using the \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test or Fisher exact test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 51 RB patients were involved in this research. The expression levels of NR1D1 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004) and NR2E3 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.024) were significantly lower in RB tumor tissues than in normal retina. The expression levels of NR1D1 and NR2E3 were less positive in RB patients with advanced stages (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.007,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.015), choroidal infiltration (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.029), and optic nerve infiltration (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.036,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003). In addition, a low expression level of NR2E3 was associated with high-risk pathology (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.025) and necrosis (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.035) of RB tissues.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The expression levels of NR1D1 and NR2E3 were decreased in RB and closely associated with the clinical stage and high invasion of the disease. These findings provide new insights into the mechanism of RB progression and suggest that NR1D1 and NR2E3 could be potential targets for treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-024-03055-3","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T22:11:35Z","timestamp":1710367895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low expression of NR1D1 and NR2E3 is associated with advanced features of retinoblastoma"],"prefix":"10.1007","volume":"44","author":[{"given":"Jie","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Qi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Nan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"issue":"6","key":"3055_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/ICU.0000000000000002","volume":"24","author":"VM Villegas","year":"2013","unstructured":"Villegas VM, Hess DJ, Wildner A, Gold AS, Murray TG (2013) Retinoblastoma. Curr Opin Ophthalmol 24(6):581\u2013588","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"3055_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/eye.2009.80","volume":"24","author":"YH Chen","year":"2010","unstructured":"Chen YH, Lin HY, Hsu WM, Lee SM, Cheng CY (2010) Retinoblastoma in Taiwan: incidence and survival characteristics from 1979 to 2003. Eye (Lond) 24(2):318\u2013322","journal-title":"Eye (Lond)"},{"issue":"8","key":"3055_CR3","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.3390\/cancers12082304","volume":"12","author":"R Kaewkhaw","year":"2020","unstructured":"Kaewkhaw R, Rojanaporn D (2020) Retinoblastoma: etiology, modeling, and treatment. Cancers 12(8):2304","journal-title":"Cancers"},{"issue":"1","key":"3055_CR4","first-page":"23","volume":"1866","author":"D Wu","year":"2016","unstructured":"Wu D, Cheung A, Wang Y, Yu S, Chan FL (2016) The emerging roles of orphan nuclear receptors in prostate cancer. Biochim Biophys Acta 1866(1):23\u201336","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"3055_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13058-019-1197-x","volume":"21","author":"H Na","year":"2019","unstructured":"Na H, Han J, Ka N-L, Lee M-H, Choi Y-L, Shin YK et al (2019) High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy. Breast Cancer Research\u202f: BCR 21(1):127","journal-title":"Breast Cancer Research : BCR"},{"issue":"1","key":"3055_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1186\/s12885-021-08597-8","volume":"21","author":"H Wang","year":"2021","unstructured":"Wang H, Fu Y (2021) NR1D1 suppressed the growth of ovarian cancer by abrogating the JAK\/STAT3 signaling pathway. BMC Cancer 21(1):871","journal-title":"BMC Cancer"},{"issue":"1","key":"3055_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/emmm.201100187","volume":"4","author":"Y-Y Park","year":"2012","unstructured":"Park Y-Y, Kim K, Kim S-B, Hennessy BT, Kim SM, Park ES et al (2012) Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med 4(1):52\u201367","journal-title":"EMBO Mol Med"},{"issue":"1","key":"3055_CR8","doi-asserted-by":"publisher","first-page":"10662","DOI":"10.1038\/s41598-017-11106-2","volume":"7","author":"T Khanal","year":"2017","unstructured":"Khanal T, Choi K, Leung Y-K, Wang J, Kim D, Janakiram V et al (2017) Loss of NR2E3 represses AHR by LSD1 reprogramming, is associated with poor prognosis in liver cancer. Sci Rep 7(1):10662","journal-title":"Sci Rep"},{"issue":"12","key":"3055_CR9","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.ophtha.2006.06.018","volume":"113","author":"CL Shields","year":"2006","unstructured":"Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT et al (2006) The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology 113(12):2276\u20132280","journal-title":"Ophthalmology"},{"issue":"8","key":"3055_CR10","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ophtha.2022.04.006","volume":"129","author":"AS Tomar","year":"2022","unstructured":"Tomar AS, Finger PT, Gallie B, Kivel\u00e4 TT, Mallipatna A, Zhang C et al (2022) High-risk pathologic features based on presenting findings in advanced intraocular retinoblastoma: a multicenter, international data-sharing american joint committee on cancer study. Ophthalmology 129(8):923\u2013932","journal-title":"Ophthalmology"},{"issue":"13","key":"3055_CR11","first-page":"4196","volume":"22","author":"HF Wang","year":"2018","unstructured":"Wang HF, Zheng SF, Chen Y, Zhou ZY, Xu J (2018) Correlations between claudin-1 and PIGF expressions in retinoblastoma. Eur Rev Med Pharmacol Sci 22(13):4196\u20134203","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"3055_CR12","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.1038\/s41467-021-25792-0","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Ottaviani D, Sefta M, Desbrousses C, Chapeaublanc E, Aschero R et al (2021) A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal\/ganglion cell gene expression. Nat Commun 12(1):5578","journal-title":"Nat Commun"},{"issue":"2","key":"3055_CR13","first-page":"1499","volume":"16","author":"X Wang","year":"2018","unstructured":"Wang X, Wang N, Wei X, Yu H, Wang Z (2018) REV-ERB\u03b1 reduction is associated with clinicopathological features and prognosis in human gastric cancer. Oncol Lett 16(2):1499\u20131506","journal-title":"Oncol Lett"},{"issue":"4","key":"3055_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.bcp.2015.06.010","volume":"96","author":"Y Wang","year":"2015","unstructured":"Wang Y, Kojetin D, Burris TP (2015) Anti-proliferative actions of a synthetic REV-ERB\u03b1\/\u03b2 agonist in breast cancer cells. Biochem Pharmacol 96(4):315\u2013322","journal-title":"Biochem Pharmacol"},{"issue":"7688","key":"3055_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature25170","volume":"553","author":"G Sulli","year":"2018","unstructured":"Sulli G, Rommel A, Wang X, Kolar MJ, Puca F, Saghatelian A et al (2018) Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature 553(7688):351\u2013355","journal-title":"Nature"},{"key":"3055_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105122","volume":"146","author":"I A\u00edsa-Mar\u00edn","year":"2020","unstructured":"A\u00edsa-Mar\u00edn I, L\u00f3pez-Iniesta MJ, Milla S, Lillo J, Navarro G, de la Villa P et al (2020) Nr2e3 functional domain ablation by CRISPR-Cas9D10A identifies a new isoform and generates retinitis pigmentosa and enhanced S-cone syndrome models. Neurobiol Dis 146:105122","journal-title":"Neurobiol Dis"},{"issue":"3","key":"3055_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017494","volume":"6","author":"NJ Mollema","year":"2011","unstructured":"Mollema NJ, Yuan Y, Jelcick AS, Sachs AJ, von Alpen D, Schorderet D et al (2011) Nuclear receptor Rev-erb alpha (Nr1d1) functions in concert with Nr2e3 to regulate transcriptional networks in the retina. PLoS ONE 6(3):e17494","journal-title":"PLoS ONE"},{"issue":"2","key":"3055_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/bjc.2013.283","volume":"109","author":"G Kapatai","year":"2013","unstructured":"Kapatai G, Brundler MA, Jenkinson H, Kearns P, Parulekar M, Peet AC et al (2013) Gene expression profiling identifies different sub-types of retinoblastoma. Br J Cancer 109(2):512\u2013525","journal-title":"Br J Cancer"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03055-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-03055-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03055-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T11:42:29Z","timestamp":1741866149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-03055-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3055"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-03055-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2750119\/v1","asserted-by":"object"}]},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]},"assertion":[{"value":"29 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments were performed following a protocol approved by the Institutional Review Board of the Eye & ENT Hospital of Fudan University. All informed consent was obtained from the subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"133"}}